Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
#2910
Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.
Aim(s): In our current preclinical work of virotherapy on neuroendocrine cancer using a panel of human NET/NEC (neuroendocrine tumor/neuroendocrine carcinoma) cell lines we employed a HSV-1 based vector named T-VEC (IMLYGIC™), which is the only EMA/FDA virotherapeutic compound approved, but so far only for advanced stages of melanoma.
Materials and methods: Oncolytic properties of T-VEC were demonstrated with the SRB cell viability assay. Virus transgene expression could be observed using the LEGEND MAX™ Human GM-CSF ELISA. Viral replication patterns were studied by sequential virus quantification. Moreover, a combinatorial treatment with the mTOR inhibitor everolimus was assessed by a real-time cell monitoring.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Lauer U
Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,
Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,
To read the full abstract, please log into your ENETS Member account.